Literature DB >> 27812924

High-Throughput Approaches to the Development of Molecular Imaging Agents.

Lina Y Hu1, Kimberly A Kelly2,3, Julie L Sutcliffe4,5,6.   

Abstract

Molecular imaging allows for the visualization of changes at the cellular level in diseases such as cancer. A successful molecular imaging agent must rely on disease-selective targets and ligands that specifically interact with those targets. Unfortunately, the translation of novel target-specific ligands into the clinic has been frustratingly slow with limitations including the complex design and screening approaches for ligand identification, as well as their subsequent optimization into useful imaging agents. This review focuses on combinatorial library approaches towards addressing these two challenges, with particular focus on phage display and one-bead one-compound (OBOC) libraries. Both of these peptide-based techniques have proven successful in identifying new ligands for cancer-specific targets and some of the success stories will be highlighted. New developments in screening methodology and sequencing technology have pushed the bounds of phage display and OBOC even further, allowing for even faster and more robust discovery of novel ligands. The combination of multiple high-throughput technologies will not only allow for more accurate identification, but also faster affinity maturation, while overall streamlining the process of translating novel ligands into clinical imaging agents.

Entities:  

Keywords:  Combinatorial library; High-throughput; Molecular imaging; OBOC; Peptides; Pet; Phage display

Mesh:

Substances:

Year:  2017        PMID: 27812924     DOI: 10.1007/s11307-016-1016-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  204 in total

1.  Molecular imaging in cancer.

Authors:  Ralph Weissleder
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

2.  A new type of synthetic peptide library for identifying ligand-binding activity.

Authors:  K S Lam; S E Salmon; E M Hersh; V J Hruby; W M Kazmierski; R J Knapp
Journal:  Nature       Date:  1991-11-07       Impact factor: 49.962

3.  Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide.

Authors:  Fan Zhang; Gang Niu; Xin Lin; Orit Jacobson; Ying Ma; Henry S Eden; Yulong He; Guangming Lu; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2011-07-19       Impact factor: 3.520

Review 4.  De novo discovery of bioactive cyclic peptides using bacterial display and flow cytometry.

Authors:  Amol V Shivange; Patrick S Daugherty
Journal:  Methods Mol Biol       Date:  2015

5.  In vivo and in vitro evaluation of Cy5.5 conjugated epidermal growth factor receptor binding peptide.

Authors:  Min-Hee Jeong; Kisu Kim; Eun-Mi Kim; Su-Jin Cheong; Chang-Moon Lee; Hwan-Jeong Jeong; Dong Wook Kim; Seok Tae Lim; Myung-Hee Sohn; Junho Chung
Journal:  Nucl Med Biol       Date:  2012-03-14       Impact factor: 2.408

6.  Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.

Authors:  Ralph J Passarella; Daniel E Spratt; Alice E van der Ende; John G Phillips; Hongmei Wu; Vasanth Sathiyakumar; Li Zhou; Dennis E Hallahan; Eva Harth; Roberto Diaz
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

7.  Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.

Authors:  Ling Chen; Yi Wang; Dengfeng Cheng; Shuping Dou; Xinrong Liu; Guozheng Liu; Donald J Hnatowich; Mary Rusckowski
Journal:  Nucl Med Commun       Date:  2011-10       Impact factor: 1.690

8.  "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity.

Authors:  R L Wahl; L E Quint; R D Cieslak; A M Aisen; R A Koeppe; C R Meyer
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

Review 9.  Molecular imaging for cancer diagnosis and surgery.

Authors:  Timon Hussain; Quyen T Nguyen
Journal:  Adv Drug Deliv Rev       Date:  2013-09-22       Impact factor: 15.470

10.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

View more
  4 in total

1.  ADAMTS4-specific MR probe to assess aortic aneurysms in vivo using synthetic peptide libraries.

Authors:  Jan O Kaufmann; Julia Brangsch; Avan Kader; Jessica Saatz; Dilyana B Mangarova; Martin Zacharias; Wolfgang E Kempf; Timm Schwaar; Marco Ponader; Lisa C Adams; Jana Möckel; Rene M Botnar; Matthias Taupitz; Lars Mägdefessel; Heike Traub; Bernd Hamm; Michael G Weller; Marcus R Makowski
Journal:  Nat Commun       Date:  2022-05-23       Impact factor: 17.694

Review 2.  Translating a radiolabeled imaging agent to the clinic.

Authors:  Gary L Griffiths; Crystal Vasquez; Freddy Escorcia; Jeff Clanton; Liza Lindenberg; Esther Mena; Peter L Choyke
Journal:  Adv Drug Deliv Rev       Date:  2021-12-20       Impact factor: 15.470

3.  Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.

Authors:  Tahleesa J Cuda; Yaowu He; Thomas Kryza; Tashbib Khan; Brian W Tse; Kamil A Sokolowski; Cheng Liu; Nicholas Lyons; Madeline Gough; Cameron E Snell; David K Wyld; Stephen Rose; Andrew D Riddell; Andrew R L Stevenson; Paul A Thomas; David A Clark; Simon Puttick; John D Hooper
Journal:  Contrast Media Mol Imaging       Date:  2021-09-13       Impact factor: 3.161

4.  Fully automated peptide radiolabeling from [18F]fluoride.

Authors:  Ryan A Davis; Chris Drake; Robin C Ippisch; Melissa Moore; Julie L Sutcliffe
Journal:  RSC Adv       Date:  2019-03-15       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.